Viking Therapeutics, Inc. (VKTX) Covered Calls

You can sell covered calls on Viking Therapeutics, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for VKTX (prices last updated Wed 4:16 PM ET):

Viking Therapeutics, Inc. (VKTX) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
65.07 +0.14 62.50 62.90 2.5M - 6.5
Covered Calls For Viking Therapeutics, Inc. (VKTX)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
May 17 65 5.40 57.50 9.4% 143%
Jun 21 65 8.80 54.10 16.3% 101%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.